Drug Profile
Research programme: stimulator of interferon genes agonists - Arbutus Biopharma
Alternative Names: HBV stimulators of interferon genes - Arbutus Biopharma; STING agonists - Arbutus BiopharmaLatest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma; Baruch S. Blumberg Institute
- Class Antivirals; Small molecules
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Hepatitis B in USA (PO)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 01 Jun 2018 Preclinical development is ongoing in USA